ATEC Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Total Revenue: $192 million, up 14% year-over-year, but below internal expectations.
Surgical Revenue: $178 million, a 17% increase year-over-year; however, a sequential decline of 6% was noted.
EOS Revenue: $14 million, down $3 million year-over-year, attributed to lower system deliveries.
EBITDA: $21 million, representing 11% of revenue, with a 97% year-over-year growth.
Gross Margin: 71.6%, an improvement of over 120 basis points year-over-year.
Cash Position: Approximately $140 million in cash, with $11 million used in the quarter, reflecting timing and intent.
Free Cash Flow: Expected to be at least $20 million for the full year.

2. Strategic Updates and Business Highlights

ATEC is focusing on enhancing its EOS Insight platform, which is evolving into a comprehensive solution that improves surgical workflows and outcomes.
The company is expanding its sales team and marketing efforts to address shortfalls in EOS sales.
Surgeon adoption is strong, with a 23% increase in new surgeon users and a 21% increase in procedural volume, indicating a durable growth model.
The company has restructured its capital facilities, securing a new Term Loan A and revolving credit facility, which simplifies its capital structure and reduces interest expenses significantly.

3. Forward Guidance and Outlook

Full Year 2026 Revenue Guidance: Approximately $882 million, reflecting 15% growth year-over-year, with surgical revenue expected to remain at $805 million (17% growth).
Surgical Case Volume Growth: Anticipated in the high teens, with average revenue per case expected to be flat.
EOS Revenue Guidance: Adjusted to approximately $77 million, reflecting updated expectations.
Adjusted EBITDA: Expected to be around $134 million, maintaining a 15% margin.

4. Bad News, Challenges, or Points of Concern

EOS Sales Performance: The quarter's results were impacted by lower-than-expected EOS sales, leading to a strategic reassessment of the sales and marketing approach.
Revenue Per Case Decline: A 3% year-over-year decline in revenue per case was noted, primarily due to a higher mix of lower-revenue cervical procedures and reduced biologics attachment rates.
Execution Issues: Challenges in the installation and execution of EOS systems have led to missed targets, causing frustration among management.
Market Conditions: The competitive landscape remains intense, with concerns about the capital environment affecting facility investments.

5. Notable Q&A Insights

Surgeon Adoption: The increase in surgeon adoption is viewed as a leading indicator of future growth, with management expressing confidence in the sustainability of this trend.
Revenue Per Case Outlook: Management indicated that while revenue per case is expected to remain flat, improvements in biologics attachment rates and the upcoming deformity season could positively influence this metric.
Confidence in Long-Term Goals: Despite short-term challenges, management reaffirmed confidence in achieving the long-range plan target of $1 billion in revenue by 2027, citing strong demand and surgeon engagement as key drivers.
Installation Challenges: The complexities associated with EOS installations were acknowledged, with management emphasizing that these issues do not reflect the overall demand for the product.

In conclusion, while ATEC faced some challenges in Q1 2026, particularly with EOS sales and revenue per case, the company remains optimistic about its growth trajectory, driven by strong surgeon adoption and strategic investments in its product offerings.

ATEC — Alphatec Holdings, Inc.